Literature DB >> 20149677

Pituitary somatostatin receptor signaling.

Anat Ben-Shlomo1, Shlomo Melmed.   

Abstract

Somatotropin-release inhibitory factor (SRIF) is a major regulator of pituitary function, mostly inhibiting hormone secretion and to a lesser extent pituitary cell growth. Five SRIF receptor subtypes (SSTR1-5) are ubiquitously expressed G-protein coupled receptors. In the pituitary, SSTR1, 2, 3 and 5 are expressed, with SSTR2 and SSTR5 predominating. As new SRIF analogs have recently been introduced for treatment of pituitary disease, we evaluate the current knowledge of cell-specific pituitary SRIF receptor signaling and highlight areas of future research for comprehensive understanding of these mechanisms. Elucidating pituitary SRIF receptor signaling enables understanding of pituitary hormone secretion and cell growth, and also encourages future therapeutic development for pituitary disorders. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20149677      PMCID: PMC2834886          DOI: 10.1016/j.tem.2009.12.003

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  141 in total

1.  A possible role of arachidonate metabolism in the mechanism of prolactin release.

Authors:  A M Judd; K Koike; R M MacLeod
Journal:  Am J Physiol       Date:  1986-03

2.  Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture.

Authors:  J Simard; F Labrie; F Gossard
Journal:  DNA       Date:  1986-08

3.  Prolonged somatostatin pretreatment desensitizes somatostatin's inhibition of receptor-mediated release of adrenocorticotropin hormone and sensitizes adenylate cyclase.

Authors:  T Reisine; J Axelrod
Journal:  Endocrinology       Date:  1983-08       Impact factor: 4.736

Review 4.  Somatostatin.

Authors:  S Reichlin
Journal:  N Engl J Med       Date:  1983-12-15       Impact factor: 91.245

5.  Somatostatin pretreatment increases the number of somatostatin receptors in GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin.

Authors:  D H Presky; A Schonbrunn
Journal:  J Biol Chem       Date:  1988-01-15       Impact factor: 5.157

Review 6.  Somatostatin mediation of adenohypophysial secretion.

Authors:  Y C Patel; C B Srikant
Journal:  Annu Rev Physiol       Date:  1986       Impact factor: 19.318

7.  Pertussis toxin blocks both cyclic AMP-mediated and cyclic AMP-independent actions of somatostatin. Evidence for coupling of Ni to decreases in intracellular free calcium.

Authors:  B D Koch; L J Dorflinger; A Schonbrunn
Journal:  J Biol Chem       Date:  1985-10-25       Impact factor: 5.157

8.  Phorbol ester and phospholipase C-induced growth hormone secretion from pituitary somatotroph adenoma cells in culture: effects of somatostatin, bromocriptine, and pertussis toxin.

Authors:  S Ikuyama; H Nawata; K Kato; S Natori; H Ibayashi
Journal:  J Clin Endocrinol Metab       Date:  1987-03       Impact factor: 5.958

9.  Stimulation of adenosine 3',5'-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro.

Authors:  L M Bilezikjian; W W Vale
Journal:  Endocrinology       Date:  1983-11       Impact factor: 4.736

10.  Somatostatin inhibits prolactin release from the lactotroph primed with oestrogen and cyproterone acetate in man.

Authors:  L J Gooren; W Harmsen-Louman; H van Kessel
Journal:  J Endocrinol       Date:  1984-12       Impact factor: 4.286

View more
  54 in total

Review 1.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 2.  Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5.

Authors:  Stefan Schulz; Andreas Lehmann; Andrea Kliewer; Falko Nagel
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

3.  Identification of Phosphorylation Sites Regulating sst3 Somatostatin Receptor Trafficking.

Authors:  Andreas Lehmann; Andrea Kliewer; Thomas Günther; Falko Nagel; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2016-04-21

Review 4.  Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.

Authors:  Rosa Maria Paragliola; Salvatore Maria Corsello; Roberto Salvatori
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 5.  Somatostatin receptor ligands in the treatment of acromegaly.

Authors:  Monica R Gadelha; Luiz Eduardo Wildemberg; Marcello D Bronstein; Federico Gatto; Diego Ferone
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 6.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

7.  Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.

Authors:  X Fan; Z Mao; D He; C Liao; X Jiang; N Lei; B Hu; X Wang; Z Li; Y Lin; X Gou; Y Zhu; H Wang
Journal:  J Endocrinol Invest       Date:  2015-06-03       Impact factor: 4.256

Review 8.  Idiopathic adult growth hormone deficiency.

Authors:  Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

9.  Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function.

Authors:  Masaaki Yamamoto; Anat Ben-Shlomo; Hiraku Kameda; Hidenori Fukuoka; Nan Deng; Yan Ding; Shlomo Melmed
Journal:  JCI Insight       Date:  2018-10-04

10.  Somatostatin receptor type 2 contributes to the self-renewal of murine embryonic stem cells.

Authors:  Xin-xiu Xu; Li-hong Zhang; Xin Xie
Journal:  Acta Pharmacol Sin       Date:  2014-07-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.